New breakthrough in microscopy and endoscopy may advance the field of precision medicine

A breakthrough in microscopy and endoscopy will soon revolutionize the study of the cellular origin of diseases, advancing the field of precision medicine. This is the goal of CRIMSON, a trans-disciplinary and trans-national research project recently funded by European Commission.

It will develop the next-generation bio-photonics imaging device for biomedical research, combining advanced laser techniques with artificial-intelligence data analysis. This groundbreaking microscope will provide three-dimensional quantitative maps of sub-cellular compartments in living cells and organoids and enable fast tissue classification with unprecedented biomolecular sensitivity.

High acquisition speed will allow the observation of intra and inter-cellular dynamic changes by time-lapse imaging.

The CRIMSON project, starting 1 December 2020, lasting 42 months and with a budget exceeding 5M€, will also simulate future in-vivo studies and demonstrate the capability to image inside the body, realizing an innovative endoscope and applying it to ex-vivo thick tissue samples. The results have potentially profound societal impacts, improving patients' quality of life and reducing public healthcare costs.

A multidisciplinary team of world-leading organizations with vertical integration of all required skills composes the consortium, coordinated by Politecnico di Milano (Italy). Three research centers (Politecnico di Milano - Italy, Leibniz Institute of Photonic Technology e.V - Germany and Centre National de la Recherche Scientifique - France), with long-standing expertise in photonics, spectroscopy and nonlinear microscopy, will develop the technology.

Three biomedical partners (Istituto Nazionale Tumori - Italy, Institut National de la Santé et de la Recherche Médicale - France and Jena University Hospital - Germany) will validate the imaging system on open biological questions related to cancer, as paradigmatic examples of the complexity and heterogeneity of cellular diseases.

Four innovative SMEs (Active Fibre Systems GmbH - Germany, Lightcore Technologies - France, Cambridge Raman Imaging Limited - UK and 3rdPlace S.r.l. - Italy), including a biomedical equipment manufacturer, will commercially exploit the innovation, thus creating a competitive advantage in the European biophotonics-related market for microscopes and R&D tools.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of AZoLifeSciences.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New Strategy to Combat Antibiotic-Resistant Bacteria